Skip to main content
. 2022 Jun 28;41(3):541–554. doi: 10.1200/JCO.21.02698

FIG 2.

FIG 2.

1L mantle cell lymphoma treatment by age and year from the Flatiron cohort: patients age (A) < 65 years (n = 1,265) and (B) ≥ 65 years (n = 2,329). aAmong 3,614 treated patients, other therapies include 9.5% of targeted agents (eg, bortezomib, lenalidomide, BTK inhibitor, and BCL-2 inhibitor), 7.8% of immunotherapy only, 4.7% of clinical trial drugs, 2.4% of chemotherapy only, and additional 1.8% of other types of chemoimmunotherapy. bNumber of patients treated between 2011 and 2020 (different from n = 1,274 in Table 1, which also includes patients treated in 2021). cCytarabine-containing regimens include all regimens with the record of cytarabine within 1L treatment (such as hyper-CVAD, NORDIC, and alternating R-CHOP/R-DHAP). 1L, first-line; BR, bendamustine plus rituximab; hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine; NORDIC, dose-intensified rituximab plus cyclophosphamide, vincristine, doxorubicin, prednisone alternating with rituximab plus high-dose cytarabine; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-DHAP, rituximab plus dexamethasone, cytarabine, and platinum.